WuXi PharmaTech Obtains ADMET Predictor License

WuXi PharmaTech has purchased a multiyear license to Simulations Plus’ ADMET Predictor, the company’s flagship structure-to-property prediction software for pharmaceutical discovery and development.
 
John DiBella, vice president of marketing and sales for Simulations Plus, said, “We’re very pleased that WuXi has elected to license the ADMET Predictor Toxicity Module, which provides more than 30 different kinds of toxicity predictions, requiring only molecular structures as input. These in silico predictions will provide WuXi with an additional service offering and are expected to assist both in prioritizing which in vitro assays need to be run for particular drugs and by filling in the gaps in in vitro data in support of pre-IND and IND filings with regulatory agencies for WuXi’s customers. This license is the result of the combined efforts of Simulations Plus and PharmoGo, our distributor in China.”